Differential expression of the NLRP3 inflammasome in adipose tissue depots suggests a new concept of tissue inflammation privilege and supports the idea that intervention at early stages of obesity, using NLRP3 inflammasome as a personalized biomarker, might prevent progression of the disease and development of co-morbidities. This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.